14 Jan 2015 16:38
14 January 2015
Electrical Geodesics, Inc
Transfer of shares between lines of stock
Electrical Geodesics, Inc. ("EGI" or the "Company"), a leading neurodiagnostic medical technology company, announces that since the announcement on 11 December 2014 a further 31,185 Common Shares are expected to be transferred from the restricted line (ISIN: USU2830P2021, TIDM: EGI) to the unrestricted line (ISIN: US28501X2018, TIDM: EGIC) on 20 January 2015.
Further to this transfer, the numbers of shares in each line will be as follows:
Line | ISIN | Balance of shares |
EGI $0.001 (Restricted) | USU2830P2021 | 21,056,057 |
EGIC $0.001 (Unrestricted) | US28501X2018 | 3,392,729 |
Total shares in issue | - | 24,448,786 |
For further information, please contact:
EGI | |
UK: Christine Soden, CFO | +44 7710 484199 |
US: Ann Bunnenberg, COO
| +1 541 687 7962 |
Peel Hunt LLP (NOMAD and Broker) | +44 (0) 20 7418 8900 |
James Steel, Clare Terlouw
| |
FTI Consulting (PR Advisors) | +44 (0) 20 3727 1000 |
Simon Conway, Mo Noonan |
About EGI
Founded in 1992, EGI designs, develops and commercialises a range of non-invasive neurodiagnostic products used to monitor and interpret brain activity based on its proprietary dense array electroencephalography ("dEEG") platform technology. The Company's technology uses up to 256 sensors, providing much higher resolution brain activity data compared to conventional 8 or 16 channel EEG and is used in medical, clinical and research settings in a diverse range of applications including important areas such as the diagnosis and monitoring of epilepsy, neurosurgical planning, sleep assessment, and many others.
EGI's dEEG systems, available in the GES 300 and now the GES 400 lines, capitalize on the Company's unique Hydrocel Geodesic Sensor Net which allows faster, easier, and more convenient placement of many EEG sensors in an even distribution over the entire scalp, providing more accurate and precise diagnosis and measurement. EGI's technology is now widely used in neuroscience research laboratories and is becoming more commonly used in clinics, care centers, and hospitals around the world. Data is measured and visualised using EGI's proprietary amplifier technology and software, providing a complete, advanced, high-resolution EEG platform. The Company's products are compatible with multiple diagnostic and imaging technologies, including magnetic resonance (MR) imaging, functional MRI (fMRI), and magneto-encephalography (MEG).
See www.egi.com for more information on the Company.
EGI.L (EGI)